NeoGenomics
NEONeoGenomics is a leading provider of oncology diagnostic testing and consultative services, operating a network of cancer-focused laboratories in the United States and the United Kingdom.
Earnings
Next report
Date not yet announcedValuation & ratios
Segments
Competitors
By market cap
By revenue growth
Profile
NeoGenomics is a leading provider of oncology diagnostic testing and consultative services, operating a network of cancer-focused laboratories in the United States and the United Kingdom. The company offers a comprehensive suite of testing modalities including cytogenetics, flow cytometry, and next-generation sequencing to support both clinical patient care and pharmaceutical research. Their core value proposition centers on delivering high-quality, rapid turnaround diagnostic results that enable precision medicine and therapy selection for cancer patients.
A leading provider of Heme oncology diagnostic testing and a key provider of solid tumor NGS solutions in the U.S. market.
FAQ
- What is NeoGenomics's market cap?
- NeoGenomics (NEO) has a market capitalization of $2.3B and trades on NASDAQ.
- What is NeoGenomics's revenue and profitability?
- NeoGenomics generated $787.8M in trailing twelve-month revenue with a net loss of $32.3M, representing a net margin of -4.1%. Gross margin stands at 44.8%. The latest reported period is Q3 2026.
- Who are NeoGenomics's competitors?
- NeoGenomics's key competitors include Myriad Genetics, Inc., Personalis, Inc. Common Stock, Tempus AI, Inc., and others. These companies compete in similar markets and product categories.
- What subsidiaries does NeoGenomics have?
- NeoGenomics's subsidiaries include Inivata.
- Where is NeoGenomics headquartered?
- NeoGenomics is headquartered in United States of America and employs approximately 2,100 people. It has been publicly traded since 1996.
